[go: up one dir, main page]

ATE268377T1 - Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll) - Google Patents

Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll)

Info

Publication number
ATE268377T1
ATE268377T1 AT01981999T AT01981999T ATE268377T1 AT E268377 T1 ATE268377 T1 AT E268377T1 AT 01981999 T AT01981999 T AT 01981999T AT 01981999 T AT01981999 T AT 01981999T AT E268377 T1 ATE268377 T1 AT E268377T1
Authority
AT
Austria
Prior art keywords
cll
lymphocytic leukemia
chronic lymphocytic
treatment
oxidative stress
Prior art date
Application number
AT01981999T
Other languages
English (en)
Inventor
David Elliott Spaner
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of ATE268377T1 publication Critical patent/ATE268377T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Aggression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01981999T 2000-10-25 2001-10-25 Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll) ATE268377T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2324199 CA2324199A1 (en) 2000-10-25 2000-10-25 Chronic lymphocytic leukemia treatment
PCT/CA2001/001497 WO2002034888A1 (en) 2000-10-25 2001-10-25 Ex vivo oxidatively stressed cll cells in chronic lymphocytic leukemia (cll) treatment

Publications (1)

Publication Number Publication Date
ATE268377T1 true ATE268377T1 (de) 2004-06-15

Family

ID=4167457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01981999T ATE268377T1 (de) 2000-10-25 2001-10-25 Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll)

Country Status (8)

Country Link
US (1) US6733748B2 (de)
EP (1) EP1330514B1 (de)
AT (1) ATE268377T1 (de)
AU (1) AU2002213700A1 (de)
CA (1) CA2324199A1 (de)
DE (1) DE60103658D1 (de)
NZ (1) NZ525275A (de)
WO (1) WO2002034888A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063995A1 (en) * 2001-10-25 2005-03-24 Spaner David E Compositions and methods for selected tumour treatment
CA2377442A1 (en) * 2002-03-20 2003-09-20 Thomas Ichim Increasing tumor oxygen content by administration of stressed cells
WO2004024171A1 (en) * 2002-09-16 2004-03-25 Vasogen Ireland Limited Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)
US20060189543A1 (en) * 2005-02-23 2006-08-24 Rosenbloom Richard A Compositions and methods for the treatment of leukemia
WO2010033771A2 (en) * 2008-09-19 2010-03-25 Trustees Of The University Of Pennsylvania Modulators of hsp70/dnak function and methods of use thereof
WO2012154818A1 (en) * 2011-05-09 2012-11-15 Biothera, Inc. B-glucan compounds, compositions, and methods
WO2015130922A2 (en) 2014-02-26 2015-09-03 The Trustees Of The University Of Pennsylvania Small molecule hsp70 inhibitors
JP2021518401A (ja) * 2018-03-21 2021-08-02 コロラド ステート ユニバーシティー リサーチ ファウンデーション がんワクチン組成物及びその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6649364B1 (en) 1995-06-07 2003-11-18 The Regents Of The University Of California Anti-apoptotic compositions and methods using same
EP1028754B1 (de) 1997-11-12 2008-08-27 The Trustees Of The University Of Pennsylvania Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
CA2244554A1 (en) 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
EP1146885B1 (de) 1999-01-12 2003-05-28 Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal Vorbehandlung gegen zelltot
CA2297448A1 (en) 2000-01-28 2001-07-28 Vasogen Inc. Improved inhibition of graft versus host disease

Also Published As

Publication number Publication date
AU2002213700A1 (en) 2002-05-06
NZ525275A (en) 2004-08-27
EP1330514A1 (de) 2003-07-30
WO2002034888A1 (en) 2002-05-02
EP1330514B1 (de) 2004-06-02
DE60103658D1 (de) 2004-07-08
US20020090358A1 (en) 2002-07-11
CA2324199A1 (en) 2002-04-25
US6733748B2 (en) 2004-05-11

Similar Documents

Publication Publication Date Title
ATE106740T1 (de) Herstellung von t-zellen und t-zellmembranen, verwendbar zur verhütung und behandlung von autoimmunkrankheiten.
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
NO20013004L (no) Anvendelse av biokjemiske substanser i en sammensetning for forhindringen og behandlingen av helsetilstander forårsaket avkonstriksjon av glattmuskelceller i organer i det menneskeligelegemet
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2191192T3 (es) Tienopirimidinas.
ATE97316T1 (de) Kosmetisches mittel und zusammensetzung zur behandlung der haut.
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
Néri et al. Ozone therapy influence in the tissue repair process: a literature review
DE60225590D1 (de) C-kithemmer zur behandlung von bakteriellen infektionen
ATE268377T1 (de) Ex-vivo unter oxidativen stress behandelte cll- zellen zur behandlung chronischer lymphozytärer läukemie (cll)
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
EP1759715A4 (de) Sterilisationssystem
ATE253117T1 (de) Adenovirus e4 proteine für induktion von zelltod
AU721530B2 (en) Endothelial lining effects and treatment of vasospastic disorders
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
BR9608147A (pt) Método para descontaminação microbiana de plaquetas sanguìneas.
AU608545B2 (en) An improved method
ATE253922T1 (de) Behandlung von stress und vorbehandlng gegen stress

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties